How Academic Researchers and Policy Experts Use DrugPatentWatch
Books and Research Papers Citing DrugPatentWatch

All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007

2011 — 2 Books and Research Papers Citing DrugPatentWatch

Manova, M., Savova, A., Stoimenova, A., et al. (2011). Economic analysis of the cost savings after implementation of antibiotic policy in hospital.
This study evaluates the financial impact of introducing a hospital-wide antibiotic policy aimed at optimizing antimicrobial use. The authors conducted an economic analysis comparing pre- and post-policy implementation costs related to antibiotic consumption. Key findings indicate significant cost savings attributed to reduced antibiotic expenditures and decreased rates of antibiotic resistance-related complications. This analysis highlights the potential for targeted hospital policies to not only improve patient outcomes but also generate substantial economic benefits.

Domingues, A. F. N., & Santana, C. C. (2012). Influência da porosidade total do leito na cromatografia preparativa em batelada dos enantiômeros do omeprazol. Embrapa.
This study investigates the impact of total bed porosity on the efficiency of batch preparative chromatography for separating omeprazole enantiomers. The researchers use simulations and experimental methods to evaluate how structural parameters in chromatographic beds influence resolution and yield, which is crucial when scaling enantiomeric separations for pharmaceutical production. From a DrugPatentWatch perspective, this work informs strategic considerations in chiral drug manufacturing, especially for drugs like omeprazole, whose enantiomeric purity affects therapeutic outcomes and patentability. Insights from this study can support CDMOs and generic manufacturers in optimizing cost-effective separation processes while ensuring compliance with regulatory expectations for stereospecific drugs—critical when preparing for post-patent entry strategies or developing differentiated formulations.